Arrowhead Research Corp  

(Public, NASDAQ:ARWR)   Watch this stock  
Find more results for Arrowhead Systems, Inc.�
+0.27 (3.74%)
Real-time:   3:24PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.02 - 7.53
52 week 4.95 - 27.63
Open 7.14
Vol / Avg. 759,531.00/1.57M
Mkt cap 411.56M
P/E     -
Div/yield     -
EPS -1.31
Shares 54.79M
Beta 2.75
Inst. own 67%
May 4, 2015
Q2 2015 Arrowhead Research Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 3, 2015
Arrowhead Research Corp Annual Shareholders Meeting
Feb 24, 2015
Arrowhead Research Corp at RBC Healthcare Conference
Feb 20, 2015
Arrowhead Research Corp Annual Shareholders Meeting (Estimated)
Feb 9, 2015
Q1 2015 Arrowhead Research Corp Earnings Call - Webcast
Feb 9, 2015
Q1 2015 Arrowhead Research Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -13221.25% -33557.38%
Operating margin -14708.80% -30443.59%
EBITD margin - -28433.29%
Return on average assets -52.50% -53.35%
Return on average equity -57.89% -60.43%
Employees 81 -
CDP Score - -


Suite 1050, 225 South Lake Avenue
United States - Map
+1-626-3043400 (Phone)
+1-626-3043401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Arrowhead Research Corporation (Arrowhead) is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its drug delivery technologies to develop drugs based on the RNA interference mechanism that silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead�s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. Arrowhead�s anti-obesity drug candidate, Adipotide, selectively destroys the blood supply that supports the growth of unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue. In April 2012, the Company acquired Alvos Therapeutics, Inc.

Officers and directors

Douglass B. Given M.D., Ph.D. Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Christopher Richard Anzalone Ph.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Kenneth Allen Myszkowski Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Bruce D. Given M.D. Chief Operating Officer
Age: 60
Bio & Compensation  - Reuters
David Lewis Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Susan Boynton Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Peter B. Leone Vice President-Strategy & Program Management
Age: 58
Bio & Compensation  - Reuters
Patrick O'Brien General Counsel
Age: 51
Bio & Compensation  - Reuters
Mauro Ferrari Ph.D Independent Director
Age: 55
Bio & Compensation  - Reuters
Edward W. Frykman Independent Director
Age: 78
Bio & Compensation  - Reuters